Gilead Sciences: How Big a Beat?
July 08, 2014 at 10:03 AM EDT
UBS analyst Matthew Roden and team are feeling pretty bullish on Gilead Sciences (GILD) heading into earnings on July 23: Special to The Chronicle In the large caps, estimates look beatable across the board, none more than GILD, where we are now 26% ahead of consensus (we raise our PT to $115)…Based on strong Rx [...]
